Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026)
Aytu Biopharma's (AYTU) quarterly Return on Capital Employed came in at 26.66% in Q1 2026, down 2165.0% year-on-year from 1.29% in Q1 2025, and down 78.0% on a QoQ basis from 14.98% in Q4 2025.
Aytu Biopharma (AYTU) Return on Capital Employed (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 16 years of Return on Capital Employed data on file, last reported at 26.66% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 2165.0% year-over-year to 26.66% in Q1 2026; TTM through Mar 2026 was 26.66%, a 2165.0% decrease from a year earlier, with the FY2025 full-year figure at 13.48%, down 1103.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 26.66%, down from 14.98% in the prior quarter.
- Over the last five years, Return on Capital Employed for AYTU reached as high as 1.84% in Q1 2024 and fell as low as 123.17% in Q2 2022.
- Historically, Return on Capital Employed has averaged 38.01% across 5 years, with a median of 14.98% in 2025.
- Across the five-year window, Return on Capital Employed slumped 7725 bps in 2022 and soared 9974 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 100.6% in 2022, then soared by 91 bps to 9.0% in 2023, then plunged by 39 bps to 12.49% in 2024, then decreased by 20 bps to 14.98% in 2025, then slumped by 78 bps to 26.66% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 26.66% in Q1 2026, 14.98% in Q4 2025, and 14.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Aytu Biopharma | 1.43 Mn | -25.28 Mn | 7.60 Mn | -26.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.66% |
| Dec 31, 2025 | -14.98% |
| Sep 30, 2025 | -14.34% |
| Jun 30, 2025 | -12.80% |
| Mar 31, 2025 | -5.00% |
| Dec 31, 2024 | -12.49% |
| Sep 30, 2024 | -2.97% |
| Jun 30, 2024 | -2.60% |
| Mar 31, 2024 | 1.84% |
| Dec 31, 2023 | -9.00% |
| Sep 30, 2023 | -23.30% |
| Jun 30, 2023 | -23.43% |
| Mar 31, 2023 | -58.01% |
| Dec 31, 2022 | -100.60% |
| Sep 30, 2022 | -118.21% |
| Jun 30, 2022 | -123.17% |
| Mar 31, 2022 | -100.45% |
| Dec 31, 2021 | -54.82% |
| Sep 30, 2021 | -40.96% |
| Jun 30, 2021 | -169.74% |